DaVita Clinical Research
will launch their new Advisory Committee Preparation Services at the 2011 Regulatory Affairs Professionals Society (RAPS):
The Regulatory Convergence
.
DCR’s team helps lead drug and device sponsors from presentation outlines through execution at FDA Advisory Committee meetings. Sponsors benefit from a strategic partnership with dedicated presentation experts who translate messages into powerful slides in real time. DCR’s team, which has participated in more than 20 advisory committee meetings during the past six years, works side-by-side with sponsors to help ensure advisory committee communication is complete and effective.
The Advisory Committee Preparation Services are divided into two segments: presentation development and presentation execution. DCR’s role in presentation development is to create slides for sponsors that serve as powerful visual aids. Then, through presentation execution services – mock rehearsals, Q&A preparation and slide retrieval – the DCR team facilitates the effective delivery of those slides for sponsors. Similar services are available for other face-to-face meetings between sponsors and FDA, such as type A/B/C meetings.
DCR is pleased to announce as a part of this expansion the addition of Lesley M. Smith to the DCR team. She recently earned a M.A. in strategic communication from the University of North Carolina at Chapel Hill. She is the only slide developer in the advisory committee preparation industry to write academically on the topic, conducting research on the presentation of data at drug advisory committee meetings.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.